Engineered donor cells take aim at tough T-Cell cancers

NCT ID NCT07220993

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 16, 2026 · Updated 40 times

Summary

This early-phase study tests a new treatment for people with T-cell leukemia or lymphoma that has come back. The treatment uses specially trained immune cells from a healthy donor, designed to recognize and attack cancer cells carrying a marker called CD7. The goal is to see if this approach is safe and can shrink tumors, though it is not expected to be a cure and ongoing management may still be needed.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Houston Methodist Hospital
NOT_YET_RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••
Texas Children's Hospital
RECRUITING

Houston, Texas, 77030, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA T-CELL ACUTE LYMPHOBLASTIC LYMPHOMA T-NON-HODGKIN LYMPHOMA T-NON-HODGKIN LYMPHOMA